echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gilead official announced that the price of Redcivir is only 10% of the lowest price of 390 US dollars/bottle of generic drugs!

    Gilead official announced that the price of Redcivir is only 10% of the lowest price of 390 US dollars/bottle of generic drugs!

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Gilead Sciencerecent recently announced a price tag for remdesivir at $390 a bottle, and most patients are expected to receive a five-day course of treatment for a total of six bottles at a price of $2,340.
    investors at least did not seem to be shocked, with Gilead's shares up about 2 percent in early trading.

    Gilead says that by helping patients get out of the hospital quickly, Redsewey should be able to immediately save the health care system net costs.
    , the only strong Phase III study so far, shows that Redsewe has reduced recovery time by four days (11 days vs 15 days, p.001) compared to placebos;
    but the price has drawn criticism from many quarters.
    this Phase III project was run by the National Institute of Allergy and Infectious Diseases (NIAID) and was therefore actually paid for by the American taxpayer, some of which believe that taxpayers should get a lower price.
    others worry that Redsewe has not yet been shown to reduce the risk of death.
    early May, the American Institute for Clinical and Economic Review (ICER) measured Redseweh's pricing and concluded that the $10 price for every 10-day course of treatment would cover production costs, regardless of investment in research and development, and that a $4,500 price would be considered cost-effective if the benefits of death were clarified.
    Related Read: Redsee Wey commercialization in the instant, Gilead odds geometry? A new analysis recently conducted by ICER found That Redsewe's $2,500-$2,800 price was cost-effective, slightly higher than Gilead's own.
    however, the ICER analysis assumes two very important factors: the inclusion of the steroid drug dexamethasone as a standard care, and the other is that Redsewe shows the benefits of death.
    the first factor seems likely to happen, with one study finding that the cheap steroid can reduce the mortality rate of patients with COVID-19 severe ventilation by a third.
    , however, the second factor is far from assured.
    in the ACTT study, NIAID found that the Redsewe group had lower mortality rates on the 14th day than the placebo group (8% vs 12%), but the difference sharply did not show a statistically significant;
    ICER concluded that if the benefits of death were not shown, Redsewe's cost-effectiveness benchmark would have fallen to $310.
    if positive signs of this survival benefit were not consistently present in Redseywe's clinical studies, Gilead may find it harder to get rid of criticism of its pricing.
    Despite this, seller analysts now have a price to simulate future sales. The chart above the
    , from EvaluatePharma, shows the current seller consensus, which includes some very different numbers.
    this partly reflects different perceptions of demand and prices in Redsewe, which were also pre-edifying the study of CAVID-19 in dexamethasone therapy.
    SVB Leerink's report said Gilead's pricing for Redsewey fell short of its expectations, though analysts still expected Gilead to make a profit from Redsewe. Analysts at Sun Trust Robinson,
    , are sceptical that redside has spent $1bn on investments this year alone, and how can Gilead recover its investment in the short term? Gilead and its investors also want to recover costs as soon as possible.
    Given that progress in the COVID-19 pandemic and other potential therapies remains unknown, this means that Redsewe's pricing needs to be as high as possible.
    it's worth noting that on the 20th of this month, two Redsiwel generics were approved for sale in India, from Cipremi and Covifor, which are priced at $39-$52 each and $65-$78 each.
    Under current guidelines of the Indian government, a case of COVID-19 patients may need to take 5-6 doses, which means the total cost of the entire course of antiviral therapy in Redsivir could be as low as $195.
    Related Read: Redseve generic drug approved in India, with total treatment costs as low as $195! Source: Gilead Final prices its Covid-19 drug.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.